Nutriband Issues Letter to Shareholders
Company Achievements and Future Outlook: Nutriband Inc. CEO Gareth Sheridan highlighted the company's significant progress in 2024, including advancements in their AVERSA™ abuse-deterrent technology, strong revenue growth, and successful partnerships, while outlining plans for regulatory submission and commercialization of their lead product, AVERSA™ Fentanyl, in 2025.
Financial Performance and Strategic Growth: The company reported record financial results driven by its contract manufacturing business, expanded global intellectual property protection, and new product launches, positioning Nutriband for continued growth and innovation in addressing the opioid crisis and enhancing patient safety.
Trade with 70% Backtested Accuracy
Analyst Views on NTRBW
No data
About the author
Nutriband Partners with Brand Institute to Create a Commercial Name for Its Abuse-Resistant Fentanyl Patch
Nutriband's Product Development: Nutriband has partnered with Brand Institute to develop a worldwide brand name and visual identity for its lead product, an abuse-deterrent fentanyl transdermal system known as AVERSA™ FENTANYL.
Technology and Safety Features: The AVERSA™ technology aims to prevent the abuse and accidental exposure of opioids, with a strong intellectual property portfolio protecting its innovations across multiple countries.
Nutriband Inc. Reports Record Q2 2025 Revenue Growth of 50.87% Year-Over-Year and Advances in NDA Filing for AVERSA Fentanyl
Financial Performance: Nutriband Inc. reported a revenue increase of 50.87% year-over-year, totaling $1,289,884 for the six months ending July 31, 2025, and holds cash reserves of $6.9 million to support product development.
Product Development: The company is advancing its lead product, AVERSA™ Fentanyl, which may become the first abuse-deterrent transdermal patch globally, with potential peak annual sales estimated between $80-$200 million.
Nutriband CEO Gareth Sheridan Seeks Nomination in Upcoming Irish Presidential Election
CEO Transition: Gareth Sheridan, CEO of Nutriband Inc., will temporarily step down to run for the Irish Presidential election, with Chairman Serguei Melnik taking over as interim CEO during this period.
AVERSA Fentanyl Development: Nutriband's AVERSA Fentanyl patch, designed to deter abuse and misuse, has received FDA approval for a meeting request, with potential annual US sales estimated between $80 million to $200 million.
FDA Grants Nutriband Meeting Request for Aversa™ Fentanyl Abuse Deterrent Fentanyl Patch
FDA Meeting for AVERSA™ FENTANYL: The FDA has scheduled a Type C Meeting on September 18, 2025, to provide feedback on the Chemistry, Manufacturing, and Controls plans for Nutriband's AVERSA™ FENTANYL, an abuse-deterrent transdermal fentanyl patch developed in partnership with Kindeva.
Potential Impact of AVERSA™ Technology: Nutriband's AVERSA™ technology aims to enhance the safety profile of transdermal drugs by preventing abuse and accidental exposure, with projected annual US sales reaching between $80 million to $200 million while addressing global pain management needs.
Nutriband Confirms Record and Pay date for 25% Preferred Stock Dividend as it Targets Filing for FDA Approval
Preferred Stock Dividend Announcement: Nutriband Inc. will issue a 25% preferred stock dividend to shareholders of record on July 25, 2025, with a pay date of August 5, 2025. Each preferred share is convertible to common stock upon FDA approval of the AVERSA Fentanyl product.
AVERSA™ Technology Overview: The company's AVERSA™ abuse-deterrent transdermal technology aims to prevent drug abuse and misuse while ensuring accessibility for patients in need. This technology is protected by patents in multiple countries.
Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030
Market Growth and Impact: The abuse-deterrent opioid market is projected to grow significantly, with revenues expected to rise from USD 25.7 million in 2024 to USD 54.8 million by 2030, while the opioid crisis continues to lead to high rates of misuse and overdose deaths in the U.S.
Innovative Solutions: Companies like Nutriband and Pfizer are developing abuse-deterrent formulations and technologies aimed at reducing opioid misuse, including the Aversa™ Fentanyl patch and updated labeling for existing medications to mitigate abuse potential.
Nutriband Partners with Brand Institute to Create a Commercial Name for Its Abuse-Resistant Fentanyl Patch
Nutriband's Product Development: Nutriband has partnered with Brand Institute to develop a worldwide brand name and visual identity for its lead product, an abuse-deterrent fentanyl transdermal system known as AVERSA™ FENTANYL.
Technology and Safety Features: The AVERSA™ technology aims to prevent the abuse and accidental exposure of opioids, with a strong intellectual property portfolio protecting its innovations across multiple countries.
Nutriband Inc. Reports Record Q2 2025 Revenue Growth of 50.87% Year-Over-Year and Advances in NDA Filing for AVERSA Fentanyl
Financial Performance: Nutriband Inc. reported a revenue increase of 50.87% year-over-year, totaling $1,289,884 for the six months ending July 31, 2025, and holds cash reserves of $6.9 million to support product development.
Product Development: The company is advancing its lead product, AVERSA™ Fentanyl, which may become the first abuse-deterrent transdermal patch globally, with potential peak annual sales estimated between $80-$200 million.
Nutriband CEO Gareth Sheridan Seeks Nomination in Upcoming Irish Presidential Election
CEO Transition: Gareth Sheridan, CEO of Nutriband Inc., will temporarily step down to run for the Irish Presidential election, with Chairman Serguei Melnik taking over as interim CEO during this period.
AVERSA Fentanyl Development: Nutriband's AVERSA Fentanyl patch, designed to deter abuse and misuse, has received FDA approval for a meeting request, with potential annual US sales estimated between $80 million to $200 million.
FDA Grants Nutriband Meeting Request for Aversa™ Fentanyl Abuse Deterrent Fentanyl Patch
FDA Meeting for AVERSA™ FENTANYL: The FDA has scheduled a Type C Meeting on September 18, 2025, to provide feedback on the Chemistry, Manufacturing, and Controls plans for Nutriband's AVERSA™ FENTANYL, an abuse-deterrent transdermal fentanyl patch developed in partnership with Kindeva.
Potential Impact of AVERSA™ Technology: Nutriband's AVERSA™ technology aims to enhance the safety profile of transdermal drugs by preventing abuse and accidental exposure, with projected annual US sales reaching between $80 million to $200 million while addressing global pain management needs.
Nutriband Confirms Record and Pay date for 25% Preferred Stock Dividend as it Targets Filing for FDA Approval
Preferred Stock Dividend Announcement: Nutriband Inc. will issue a 25% preferred stock dividend to shareholders of record on July 25, 2025, with a pay date of August 5, 2025. Each preferred share is convertible to common stock upon FDA approval of the AVERSA Fentanyl product.
AVERSA™ Technology Overview: The company's AVERSA™ abuse-deterrent transdermal technology aims to prevent drug abuse and misuse while ensuring accessibility for patients in need. This technology is protected by patents in multiple countries.
Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030
Market Growth and Impact: The abuse-deterrent opioid market is projected to grow significantly, with revenues expected to rise from USD 25.7 million in 2024 to USD 54.8 million by 2030, while the opioid crisis continues to lead to high rates of misuse and overdose deaths in the U.S.
Innovative Solutions: Companies like Nutriband and Pfizer are developing abuse-deterrent formulations and technologies aimed at reducing opioid misuse, including the Aversa™ Fentanyl patch and updated labeling for existing medications to mitigate abuse potential.
